- Investing Ideas
- /
- Global Established, Profitable and Undervalued
Global Established, Profitable and Undervalued
UPDATED Aug 11, 2022
Over $1bn in market cap, profitable and undervalued based on cash flows.
1,059 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| NBIXNeurocrine Biosciences | US$104.88 | 9.3% | 21.0% | US$10.0b | US$115.32 | PE821.7x | E40.5% | n/a | Pharmaceuticals & Biotech | ||
| SCBSCB X | ฿105.00 | 4.0% | 9.1% | ฿353.5b | ฿136.43 | PB0.8x | E10.6% | 5.0% | Banks | ||
| KBANKKasikornbank | ฿149.00 | 2.8% | 41.9% | ฿353.0b | ฿177.87 | PB0.7x | E11.7% | 2.2% | Banks |